NCT07102511View on ClinicalTrials.gov

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

June 30, 2027

Conditions
Familial Hypercholesterolemia - Heterozygous
Interventions
BIOLOGICAL

lerodalcibep 300 mg Monthly SC

lerodalcibep or placebo

Trial Locations (3)

2193

Lipid Clinic Wits University, Johannesburg

35100

Ege Universitesi Tip Fakultesi, Izmir

45227

Metabolic & Atherosclerosis Research Center, Cincinnati

Sponsors
All Listed Sponsors
lead

LIB Therapeutics LLC

INDUSTRY

NCT07102511 - Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH | Biotech Hunter | Biotech Hunter